Elevated Liver Enzymes in Liver Disease and Tuberculosis

Correlation Between Elevated Transaminases and Liver Disease

Elevated ALT and AST values strongly correlate with ongoing liver damage in patients with liver cirrhosis, liver cancer, and tuberculosis, particularly when receiving anti-tuberculosis medications 1, 2
For patients with liver cancer and cirrhosis, ALT values up to 5× upper limit of normal (ULN) may be expected due to underlying liver disease 2
Elevated transaminases directly reflect hepatocellular injury and necrosis caused by diffuse hepatic infiltration, hepatitis, or toxic injury 3

Anti-tuberculosis medications, particularly isoniazid, rifampicin, and pyrazinamide, are known to cause hepatotoxicity 4
For patients with pre-existing liver disease, more careful monitoring of liver function is required during TB treatment (weekly for two weeks, then biweekly for the first two months) 4

The severity of abnormal aminotransferases can be classified as:
- Mild: <5 times the upper reference limit 3
- Moderate: 5-10 times the upper reference limit 3
- Severe: >10 times the upper reference limit 3

For patients with liver cirrhosis and cancer receiving TB treatment:
- If AST/ALT rises to five times normal or bilirubin rises, stop rifampicin, isoniazid, and pyrazinamide immediately 4
- Consider alternative TB regimens with less hepatotoxic potential 5
Monitoring recommendations:
- Measure serum aminotransferases and total bilirubin every 1-4 weeks for at least the first 2-3 months of TB treatment 5
- Monitor INR periodically for patients with severe hepatic impairment 5

Patients with liver cirrhosis and cancer may have baseline abnormal liver function tests, making it challenging to determine the cause of worsening transaminases 1, 2
ALT activity might be affected by factors other than liver disease, including body mass index, gender, abnormal lipid and carbohydrate metabolism, and uremia 6